Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
| Health Care Equipment & Supplies Industry | Healthcare Sector | John F. Sheridan CEO | XDUS Exchange | US8753722037 ISIN |
| US Country | 2,500 Employees | 10 Oct 2017 Last Dividend | 10 Oct 2017 Last Split | 14 Nov 2013 IPO Date |
Tandem Diabetes Care, Inc. is a leading medical device company dedicated to enhancing the lives of individuals with diabetes worldwide through innovative technology solutions. Originating as Phluid Inc., the company was rebranded to Tandem Diabetes Care, Inc. in January 2008, reflecting its focused mission on diabetes management solutions. Since its incorporation in 2006, Tandem Diabetes Care has been committed to development, design, and commercialization efforts centered around advancing diabetes care. Headquartered in San Diego, California, Tandem offers a wide array of products that significantly improve the management of diabetes for its users in the United States and across the globe.